Buffy coat-derived platelets cryopreserved using a new method: Results from a pivotal clinical trial on thrombocytopenic patients with acute leukaemia. (December 2019)

• Record Type: Journal Article
• Authors: Napolitano, Mariasanta; Mancuso, Salvatrice; Raso, Simona; LoCoco, Lucio; Arfò, Piera Stefania; De Francisci, Giovanni; Dieli, Francesco; Caccamo, Nadia; Reina, Amalia; Dolce, Alberto; Agliastro, Rosalia; Siragusa, Sergio
• Is Part Of: Transfusion and apheresis science. Volume 58:Number 6(2019)
• Publication Date: 2019-12
• Subjects: Cryopreserved platelets -- Severe thrombocytopenia -- Acute leukaemia -- Safety -- Transfusion; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2019.10.008
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: The administration of cryopreserved platelets (PLTs) may overcome the limits of platelet shortage and availability, especially during some seasons or in specific contexts like rural areas. After in vitro validation studies, ad hoc prepared buffy coat-derived pooled platelet concentrates (BC-PLTs), treated with dimethyl sulphoxide (DMSO) and cryopreserved (CRY BC-PLTs) at -80 °C with a modified Valeri method, were transfused in patients with severe thrombocytopenia secondary to chemotherapy for acute leukaemia (AL). Five inpatients were enrolled in the pivotal clinical trial NCT02032134: 4 males and 1 female with a mean age of 71 years (range: 65–80). Four patients were diagnosed with acute myeloid leukaemia and 1 had acute lymphoblastic leukaemia.Transfusion of one Unit of CRY BC-PLTs resulted effective in active bleeding control in two patients without any adverse reaction or concomitant antihaemorrhagic therapies. CRY BC-PLTs met the currently accepted criteria for cryopreserved PLTs, their transfusion in patients with AL was safe. (Clinical trial: NCT02032134).